BIOHARVEST SCIENCES INC

BioHarvest Sciences will list its common shares on the Tel Aviv Stock Exchange (TASE) in addition to the NASDAQ, with trading scheduled to begin on 8 September 2026. The company applied to register all 22,667,842 outstanding common shares as well as up to 4,516,021 shares for the employee share plan and 610,742 shares from warrants. The share will trade on the TASE under the ticker BHST in English and “בהסט” in Hebrew. The aim of the secondary listing is to broaden access to the shares and strengthen ties with the Israeli investment community; future EDGAR filings will be submitted concurrently via MAGNA. » Más en de.investing.com

At an investor conference BioHarvest Sciences presented its "Botanical Synthesis" platform, announced an expansion of production and a new facility with 20–25 tonnes capacity, and highlighted roughly $100 million in investments and 15 patents. Revenue in 2025 was about $35 million, VINIA cumulative revenue exceeded $100 million; for 2026 a D2C revenue of $33–35 million and consolidated revenue of $37–40 million is expected. The company cited a supply agreement for a fragrance molecule totaling 20 tonnes (valued at $20–30 million for 2027–28) and says it holds 20% of that molecule as well as 25% of a saffron molecule. BioHarvest emphasizes shifting the business from development revenue toward manufacturing and royalties and is using AI for process optimization and quality control. » Más en de.investing.com

BioHarvest Sciences reported Q1 revenue of $8.5m, up 8% year‑over‑year, and maintained full‑year guidance of $42m–$48m. CDMO revenue grew 135% driven by progress in fragrance and saffron Botanical Synthesis programs, including Stage 2 agreements valued at over $2m. Net loss widened to $2.6m and adjusted EBITDA loss was $1.2m; cash totaled $20.2m at quarter end. The VINIA D2C business accounted for 95% of sales with 90,000 active users and new product momentum, while the company plans a new manufacturing site operational in H2 2027 and named Nedira Salzman‑Frenkel VP of CDMO business development. » Más en finance.yahoo.com